Format

Send to

Choose Destination
Bone Marrow Transplant. 2019 Jan;54(1):26-34. doi: 10.1038/s41409-018-0227-0. Epub 2018 May 24.

Prevention and treatment of relapse after stem cell transplantation by cellular therapies.

Author information

1
Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.
2
Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
3
Vita-Salute San Raffaele University, Milan, Italy.
4
Division of Hematology/Oncology, Blood and Marrow Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, USA.
6
Hematology Department, AP-HP, Saint Antoine Hospital, Paris, France.
7
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. nkroeger@uke.uni-hamburg.de.
8
Kolb Consulting, München, Germany.

Abstract

Despite recent advances in reducing therapy-related mortality after allogeneic stem cell transplantation (alloSCT) relapse remains the major cause of treatment failure and little progress has been achieved in the last decades. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg/Germany in November 2016 international experts presented and discussed recent developments in the field. Here, the potential of cellular therapies including unspecific and specific T cells, genetically modified T cells, CAR-T cells, NK-cells, and second allografting in prevention and treatment of relapse after alloSCT are summarized.

PMID:
29795426
DOI:
10.1038/s41409-018-0227-0

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center